- Home
- DNTH vs AUTL Comparison
DNTH vs AUTL Comparison
Compare DNTH & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- AUTL
- Stock Information
- Founded
- DNTH 2015
- AUTL 2014
- Country
- DNTH United States
- AUTL United Kingdom
- Employees
- DNTH N/A
- AUTL N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DNTH Health Care
- AUTL Health Care
- Exchange
- DNTH Nasdaq
- AUTL Nasdaq
- Market Cap
- DNTH 724.8M
- AUTL 590.8M
- IPO Year
- DNTH N/A
- AUTL 2018
- Fundamental
- Price
- DNTH $23.67
- AUTL $1.95
- Analyst Decision
- DNTH Strong Buy
- AUTL Strong Buy
- Analyst Count
- DNTH 9
- AUTL 3
- Target Price
- DNTH $46.43
- AUTL $10.20
- AVG Volume (30 Days)
- DNTH 198.9K
- AUTL 1.2M
- Earning Date
- DNTH 03-20-2025
- AUTL 03-13-2025
- Dividend Yield
- DNTH N/A
- AUTL N/A
- EPS Growth
- DNTH N/A
- AUTL N/A
- EPS
- DNTH N/A
- AUTL N/A
- Revenue
- DNTH $5,366,000.00
- AUTL $10,091,000.00
- Revenue This Year
- DNTH $100.14
- AUTL $851.88
- Revenue Next Year
- DNTH N/A
- AUTL $220.57
- P/E Ratio
- DNTH N/A
- AUTL N/A
- Revenue Growth
- DNTH 51.41
- AUTL 82.71
- 52 Week Low
- DNTH $18.35
- AUTL $1.87
- 52 Week High
- DNTH $33.77
- AUTL $6.63
- Technical
- Relative Strength Index (RSI)
- DNTH 53.31
- AUTL 37.49
- Support Level
- DNTH $22.77
- AUTL $1.92
- Resistance Level
- DNTH $25.46
- AUTL $2.15
- Average True Range (ATR)
- DNTH 1.49
- AUTL 0.12
- MACD
- DNTH 0.13
- AUTL 0.01
- Stochastic Oscillator
- DNTH 57.18
- AUTL 22.22
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.